+

PE20181025A1 - Inhibidores de ezh2 - Google Patents

Inhibidores de ezh2

Info

Publication number
PE20181025A1
PE20181025A1 PE2018000313A PE2018000313A PE20181025A1 PE 20181025 A1 PE20181025 A1 PE 20181025A1 PE 2018000313 A PE2018000313 A PE 2018000313A PE 2018000313 A PE2018000313 A PE 2018000313A PE 20181025 A1 PE20181025 A1 PE 20181025A1
Authority
PE
Peru
Prior art keywords
methyl
compounds
cyclohexyl
ethyl
refers
Prior art date
Application number
PE2018000313A
Other languages
English (en)
Inventor
Esteban Dominguez
Deqi Guo
Mary Margaret Mader
Anh-Quan Hannah Nguyen
Prado Miriam Filadelfa Del
Michael Enrico Richett
Michael John Rodriguez
Yvonne Yee Mai Yip
Kuo-Long Yu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20181025A1 publication Critical patent/PE20181025A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se refiere a compuestos que inhiben la actividad de la histona lisina metiltransferasa, potenciador del homologo de Zeste 2 (EZH2), donde: X es -CH2- o -CH2-CH2-; Y' es -NR4R5, -CH(CH3)-ciclohexil-4-il-N-metil-N-metoxietilo, entre otros; R4 es ciclohex-4-il sustituido con N-metil-N-metoxietilamino, N-metil-N-ciclopropilamino, entre otros; R5 es metilo o etilo; R6 es metilo o cloro. Tambien se refiere a una composicion y a una combinacion que comprende a dichos compuestos. Un compuesto preferido es 5-[(4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil]-2-{(1R)-1-[4-(3-metoxiazetidin-1-il)ciclohexil]etil}-3-metil-5,6,7,8-tetrahidro-4H-tieno[3,2-c]azepin-4-ona. Dichos compuestos son utiles para el tratamiento del cancer tales como cancer de ovario, gastrico, colorrectal, entre otros
PE2018000313A 2015-08-27 2016-08-22 Inhibidores de ezh2 PE20181025A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382433 2015-08-27
EP15382615 2015-12-11

Publications (1)

Publication Number Publication Date
PE20181025A1 true PE20181025A1 (es) 2018-06-27

Family

ID=56801893

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000313A PE20181025A1 (es) 2015-08-27 2016-08-22 Inhibidores de ezh2

Country Status (31)

Country Link
US (1) US9718838B2 (es)
EP (1) EP3341379B1 (es)
JP (1) JP6704040B2 (es)
KR (1) KR20180030704A (es)
CN (1) CN107922434B (es)
AU (1) AU2016313541A1 (es)
BR (1) BR112018003108A2 (es)
CA (1) CA2994428A1 (es)
CO (1) CO2018002033A2 (es)
CR (1) CR20180104A (es)
CY (1) CY1122364T1 (es)
DK (1) DK3341379T3 (es)
DO (1) DOP2018000058A (es)
EC (1) ECSP18014798A (es)
ES (1) ES2756603T3 (es)
HR (1) HRP20192101T1 (es)
HU (1) HUE047630T2 (es)
IL (1) IL257061A (es)
LT (1) LT3341379T (es)
MD (1) MD3341379T2 (es)
ME (1) ME03650B (es)
MX (1) MX2018002484A (es)
PE (1) PE20181025A1 (es)
PH (1) PH12018500423A1 (es)
PL (1) PL3341379T3 (es)
PT (1) PT3341379T (es)
RS (1) RS59615B1 (es)
SI (1) SI3341379T1 (es)
TN (1) TN2018000058A1 (es)
TW (1) TW201718598A (es)
WO (1) WO2017035060A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU783054B2 (en) * 1999-04-22 2005-09-22 Biogen Ma Inc. Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
TW201708210A (zh) * 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑
CN109328188A (zh) 2016-05-05 2019-02-12 葛兰素史密斯克莱知识产权（第2 号）有限公司 Zeste增强子同源物2抑制剂
CN109312407A (zh) * 2016-06-08 2019-02-05 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
PL3746446T3 (pl) 2018-01-31 2022-08-29 Mirati Therapeutics, Inc. Inhibitory PRC2
WO2019206155A1 (zh) * 2018-04-24 2019-10-31 上海海雁医药科技有限公司 Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用
WO2020011607A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
WO2020247475A1 (en) 2019-06-05 2020-12-10 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
CN116239519A (zh) * 2023-02-20 2023-06-09 安徽峆一药业股份有限公司 一种(2-苄氧基-4,6-二甲基吡啶-3-基)甲醇的合成方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1303261B1 (en) * 2000-07-24 2005-03-09 Pharmacia & Upjohn Company Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
JP2004524277A (ja) * 2000-10-20 2004-08-12 ブリストル−マイヤーズ スクイブ ファーマ カンパニー アシルセミカルバジド及びサイクリン依存性キナーゼ（ｃｄｋ）阻害剤としてのその使用
JP2005508322A (ja) * 2001-09-24 2005-03-31 ジェシー エル エス オウ 併用療法に用いられるスラミンの化学増感用量を決定するための方法及び成分
EP1620449A4 (en) 2003-02-14 2008-10-01 Smithkline Beecham Corp NUCLEIC ACIDS WITH DIFFERENTIAL EXPRESSION THAT CORRELATE WITH KSP EXPRESSION
WO2011140325A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
ES2528269T3 (es) 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
CA2798622C (en) 2010-05-07 2016-11-15 Glaxosmithkline Llc Indoles
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2012075080A1 (en) 2010-12-01 2012-06-07 Glaxosmithkline Llc Indoles
AU2012223448B2 (en) 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
WO2013039988A1 (en) 2011-09-13 2013-03-21 Glax0Smithkline Llc Azaindazoles
CA2850570A1 (en) 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
WO2013067302A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
CA2854447A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
WO2013067300A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2953941B1 (en) 2013-02-11 2017-04-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013120104A2 (en) 2012-02-10 2013-08-15 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
KR20230145531A (ko) * 2012-03-12 2023-10-17 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
WO2013155434A1 (en) 2012-04-12 2013-10-17 E. I. Du Pont De Nemours And Company Can tap
JP6255382B2 (ja) 2012-04-13 2017-12-27 エピザイム，インコーポレイティド ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態
BR112014025506B1 (pt) 2012-04-13 2024-02-06 Epizyme, Inc Composição que compreende composto inibidor de ezh2, uso terapêutico da mesma e método in vitro de inibição da proliferação de células de câncer
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
WO2013181462A1 (en) * 2012-05-31 2013-12-05 Amgen Inc. Use of amg 900 for the treatment of cancer
US20150239842A1 (en) 2012-09-28 2015-08-27 Pfizer Inc. Benzamide and heterobenzamide compounds
IL288181B2 (en) 2012-10-15 2024-04-01 Epizyme Inc Cancer treatment methods
SG11201502803VA (en) 2012-10-15 2015-05-28 Epizyme Inc Substituted benzene compounds
CN104968646B (zh) 2012-12-13 2017-09-05 葛兰素史密斯克莱有限责任公司 Zeste同源物增强子2的抑制剂
WO2014100080A1 (en) 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
CA2894222A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
WO2014100646A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9505745B2 (en) * 2013-04-30 2016-11-29 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
CA2917463A1 (en) 2013-07-10 2015-01-15 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
WO2015010078A2 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
JP2016533364A (ja) 2013-10-18 2016-10-27 エピザイム，インコーポレイティド 癌を処置する方法
WO2015077193A1 (en) 2013-11-19 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015077194A1 (en) 2013-11-22 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015104677A1 (en) 2014-01-10 2015-07-16 Piramal Enterprises Limited Heterocyclic compounds as ezh2 inhibitors
ES2774900T3 (es) 2014-03-17 2020-07-23 Daiichi Sankyo Co Ltd Derivados de 1,3-benzodioxol como inhibidores de EZH1 y/o EZH2
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
IL285201B2 (en) 2014-06-17 2024-05-01 Epizyme Inc EZH2 inhibitors for the treatment of lymphoma
MY185765A (en) 2014-06-17 2021-06-06 Pfizer Substituted dihydroisoquinolinone compounds
KR20170020463A (ko) 2014-06-19 2017-02-22 메모리얼 슬로안-케터링 캔서 센터 Ezh2 저해제에의 반응에 대한 바이오마커
EP3160940A4 (en) 2014-06-25 2018-05-02 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
KR20170068603A (ko) 2014-10-28 2017-06-19 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 제스트 인핸서 상동체 2 억제제
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2016102493A1 (en) 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors
US20180037568A1 (en) 2015-02-13 2018-02-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2016140501A1 (en) 2015-03-04 2016-09-09 Kainos Medicine, Inc. Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors
TW201708210A (zh) 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑

Also Published As

Publication number Publication date
CO2018002033A2 (es) 2018-05-21
CR20180104A (es) 2018-04-24
TW201718598A (zh) 2017-06-01
MX2018002484A (es) 2018-06-15
ES2756603T3 (es) 2020-04-27
RS59615B1 (sr) 2020-01-31
AU2016313541A1 (en) 2018-02-15
EP3341379A1 (en) 2018-07-04
SI3341379T1 (sl) 2019-11-29
ECSP18014798A (es) 2018-04-30
CN107922434B (zh) 2020-06-19
PH12018500423A1 (en) 2018-08-29
DK3341379T3 (da) 2019-12-02
CN107922434A (zh) 2018-04-17
PL3341379T3 (pl) 2020-05-18
CA2994428A1 (en) 2017-03-02
HUE047630T2 (hu) 2021-12-28
JP6704040B2 (ja) 2020-06-03
WO2017035060A1 (en) 2017-03-02
KR20180030704A (ko) 2018-03-23
IL257061A (en) 2018-03-29
EP3341379B1 (en) 2019-10-09
DOP2018000058A (es) 2018-03-30
MD3341379T2 (ro) 2020-01-31
HRP20192101T1 (hr) 2020-02-21
PT3341379T (pt) 2019-12-16
BR112018003108A2 (pt) 2018-09-25
US9718838B2 (en) 2017-08-01
TN2018000058A1 (en) 2019-07-08
JP2018530527A (ja) 2018-10-18
LT3341379T (lt) 2019-12-10
US20170066780A1 (en) 2017-03-09
CY1122364T1 (el) 2021-01-27
ME03650B (me) 2020-07-20

Similar Documents

Publication Publication Date Title
PE20181025A1 (es) Inhibidores de ezh2
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201792231A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201690306A1 (ru) Ингибиторы ido
EA201591599A1 (ru) Ингибиторы ido
EA201690027A1 (ru) Ингибиторы ido
EA201591823A1 (ru) Ингибиторы ido
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201790992A1 (ru) Иммунорегуляторные агенты
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA202191519A1 (ru) Модуляторы trex1
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
EA201790070A1 (ru) Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载